Outcome of treatment of recurrent glioblastoma multiforme in elderly and/or frail patients

详细信息    查看全文

• 作者：Joanna Socha ; Lucyna Kepka ; Sunita Ghosh ; Wilson Roa…
• 关键词：Recurrent glioblastoma multiforme ; Elderly patients ; Frail patients ; Salvage therapy
• 刊名：Journal of Neuro-Oncology
• 出版年：2016
• 出版时间：February 2016
• 年：2016
• 卷：126
• 期：3
• 页码：493-498
• 全文大小：560 KB
• 参考文献：1.Boyle P, Maisonneuve R, Muir C (1990) Is the increased incidence of primary brain tumours in the elderly real? J Natl Cancer Inst 82:1594–1596PubMed CrossRef
  2.Greig N, Ries L, Yanick R et al (1990) Increasing annual incidence of primary malignant brain tumours in the elderly. J Natl Cancer Inst 82:1621–1624PubMed CrossRef
  3.Hess KR, Broglio KR, Bondy ML (2004) Adult glioma incidence trends in the United States, 1977-2000. Cancer 101:2293–2299PubMed CrossRef
  4.Ferguson M, Rodrigues G, Cao J et al (2014) Management of high-grade gliomas in the elderly. Semin Radiat Oncol 24:279–288PubMed CrossRef
  5.Ohgaki H, Dessen P, Jourde B et al (2004) Genetic pathways to glioblastoma: a population-based study. Cancer Res 64:6892–6899PubMed CrossRef
  6.Wrensch M, Minn Y, Chew T et al (2002) Epidemiology of primary brain tumors: current concepts and review of the literature. Neuro Oncol 4:278–299PubMed PubMedCentral
  7.Laperriere N, Weller M, Stupp R et al (2013) Optimal management of elderly patients with glioblastoma. Cancer Treat Rev 39:350–357PubMed CrossRef
  8.NCCN Clinical Practice Guidelines in Oncology. Central Nervous System Cancers. Version 1.2015. Available from: http://​nccn.​org/​
  9.Li J, Wang M, Won M et al (2011) Validation and simplification of the Radiation Therapy Oncology Group recursive partitioning analysis classification for glioblastoma. Int J Radiat Oncol Biol Phys 81:623–630PubMed PubMedCentral CrossRef
  10.Keime-Guibert F, Chinot O, Taillandier L et al (2007) Association of French-speaking neuro-oncologists. Radiotherapy for glioblastoma in the elderly. N Engl J Med 356:1527–1535PubMed CrossRef
  11.Yin AA, Zhang LH, Cheng JX et al (2013) Radiotherapy plus concurrent or sequential temozolomide for glioblastoma in the elderly: a meta-analysis. PLoS One 8:e74242PubMed PubMedCentral CrossRef
  12.Roa W, Kepka L, Kumar N, et al. (2015) An IAEA randomized phase III study of radiation therapy in elderly and/or frail patients with newly diagnosed glioblastoma multiforme. J Clin Oncol 2015, JCO.2015.62.6606; published online on September 21, 2015
  13.Nieder C, Grosu AL, Molls M (2000) A comparison of treatment results for recurrent malignant gliomas. Cancer Treat Rev 26:397–409PubMed CrossRef
  14.Easaw JC, Mason WP, Perry J et al (2011) Canadian Glioblastoma Recommendations Committee. Canadian recommendations for the treatment of recurrent or progressive glioblastoma multiforme. Curr Oncol 18:e126–e136PubMed PubMedCentral CrossRef
  15.Barker FG 2nd, Chang SM, Gutin PH et al (1998) Survival and functional status after resection of recurrent glioblastoma multiforme. Neurosurgery 42:709–723PubMed CrossRef
  16.Pinsker M, Lumenta C (2001) Experiences with reoperation on recurrent glioblastoma multiforme. Zentralbl Neurochir 62:43–47PubMed CrossRef
  17.Quick J, Gessler F, Dützmann S et al (2014) Benefit of tumor resection for recurrent glioblastoma. J Neurooncol 117:365–372PubMed CrossRef
  18.Kim HR, Kim KH, Kong DS et al (2015) Outcome of salvage treatment for recurrent glioblastoma. J Clin Neurosci 22:468–473PubMed CrossRef
  19.Park JK, Hodges T, Arko L et al (2010) Scale to predict survival after surgery for recurrent glioblastoma multiforme. J Clin Oncol 28:3838–3843PubMed PubMedCentral CrossRef
  20.Taal W, Oosterkamp HM, Walenkamp AM et al (2014) Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. Lancet Oncol 15:943–953PubMed CrossRef
  21.Wick W, Platten M, Meisner C et al (2012) Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol 13:707–715PubMed CrossRef
  22.Malmström A, Grønberg BH, Marosi C et al (2012) Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol 13:916–926PubMed CrossRef
  23.NCT00482677: A randomized phase III study of temozolomide and short-course radiation versus short-course radiation alone in the treatment of newly diagnosed glioblastoma multiforme in elderly patients. https://​clinicaltrials.​gov/​ct2/​show/​NCT00482677
  
• 作者单位：Joanna Socha (1)
  Lucyna Kepka (2)
  Sunita Ghosh (3)
  Wilson Roa (3)
  Narendra Kumar (4)
  Valery Sinaika (5)
  Juliana Matiello (6)
  Darejan Lomidze (7)
  Douglas Guedes de Castro (8)
  Dalenda Hentati (9)
  Elena Fidarova (10)
  
  1. Department of Radiotherapy, Regional Oncology Center, ul. Bialska 104/118, 42-200, Czestochowa, Poland
  2. Independent Public Care Facility of the Ministry of the Interior and Warmian & Mazurian Oncology Center, Olsztyn, Poland
  3. Department of Radiotherapy, Alberta Health Services-Cancer/University of Alberta, Edmonton, Canada
  4. Department of Radiotherapy & Oncology, Post Graduate Institute of Medical Education & Research (PGIMER), Chandigarh, India
  5. Department of Radiotherapy, N.N. Alexandrov National Cancer Centre of Belarus, Minsk, Belarus
  6. Department of Radiotherapy, Irmandade da Santa Casa de Misericórdia de Porto Alegre, Porto Alegre, Brazil
  7. Department of Radiotherapy, High Technology Medical Center University Clinic, Tbilisi, Georgia
  8. Department of Radiotherapy, A C Camargo Hospital, São Paolo, Brazil
  9. Department of Radiotherapy, Institut National de Cancer Salah Azaiz, Tunis, Tunisia
  10. Applied Radiation Biology and Radiotherapy Section, International Atomic Energy Agency, Vienna, Austria
  
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Oncology
  
• 出版者：Springer Netherlands
• ISSN：1573-7373

文摘

Optimal treatment of recurrent glioblastoma multiforme (rGBM) in elderly and/or frail patients remains virtually unexplored, the best supportive care (BSC) only is routinely administered due to the fatal prognosis. We evaluated the impact of different treatment methods on post-progression survival (PPS) and overall survival (OS) of such patients. Data from 98 elderly and/or frail rGBM patients, treated initially with 1-week or 3-week radiotherapy (RT) within the phase III IAEA study (2010–2013), were analyzed. KPS at relapse and salvage treatment methods were recorded. Kaplan–Meier method was used to estimate PPS and OS for different treatment modalities. Eighty-four patients experienced recurrence: 47 (56 %) received BSC, 21 (25 %)—chemotherapy (CHT), 8 (9.5 %)—surgery, 3 (3.5 %)—RT, for 5 (6 %) the data was unavailable. Median OS from randomization for all 84 patients was 35 weeks: 55 versus 30 weeks for any treatment versus BSC, p < 0.0001. Median PPS was 15 weeks: 23 weeks with any treatment versus 9 weeks with BSC, p < 0.0001. For local treatment (surgery and/or RT) median PPS was 51 versus 21 weeks for CHT, p = 0.36. In patients with poor KPS (≤60) at relapse median PPS was 9 weeks with BSC versus 21 weeks with any treatment, p = 0.014. In poor KPS patients median PPS for local treatment was 14 weeks versus 21 weeks with CHT, p = 0.88. An active therapeutic approach may be beneficial for selected elderly and/or frail rGBM patients. Poor KPS patients may also benefit from active treatment, but there is no benefit of local treatment over CHT. Keywords Recurrent glioblastoma multiforme Elderly patients Frail patients Salvage therapy